Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    NEXT STORY
    Iterum Therapeutics to Announce Fourth Quarter and Full Year 2020 Financial Results and Host Conference Call on March 12, 2021
    PREV STORY
    Recruitment and Enrollment Underway at Eight Sites for Innovation Pharma’s Phase 2 Clinical Trial of Brilacidin for COVID-19
    Subscribe to PM360
    Print Subscription
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    NEXT STORY
    Iterum Therapeutics to Announce Fourth Quarter and Full Year 2020 Financial Results and Host Conference Call on March 12, 2021
    PREV STORY
    Recruitment and Enrollment Underway at Eight Sites for Innovation Pharma’s Phase 2 Clinical Trial of Brilacidin for COVID-19
    Subscribe to PM360
    Print Subscription
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    AnaptysBio Announces Positive Top-Line Proof-of-Concept Data For ANB020 In Moderate-to-Severe Baseline Adult Peanut Allergy Patients

    46% of adult peanut allergy patients with moderate-to-severe baseline symptoms tolerated 500mg cumulative peanut ...

    author_avatar
    NASDAQ Market News

    Telix Pharmaceuticals Limited Lists on the Australian Securities Exchange

    MELBOURNE, Australia, Nov. 15, 2017 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX.TLX) (“Telix”, the ...

    author_avatar
    NASDAQ Market News

    Coherus BioSciences to Report First Quarter 2018 Financial Results on May 10th  

    author_avatar
    NASDAQ Market News